TY - JOUR
T1 - Impact of care coordination on oral anticoagulant therapy among patients with atrial fibrillation in routine clinical practice in Japan
T2 - A prospective, observational study
AU - Ono, Fumiko
AU - Akiyama, Sayako
AU - Suzuki, Akifumi
AU - Ikeda, Yoshinobu
AU - Takahashi, Akira
AU - Matsuoka, Hitoshi
AU - Sasaki, Masahiro
AU - Okamura, Tomonori
AU - Yoshihara, Nariaki
N1 - Funding Information:
The authors are thankful to the members of t the Akita study group (Additional file 1) for their participation in this study; Kazuya Sasaki, Sasaki Internal Medicine Clinic; Yoshiya Toyoshima, Toyoshima Clinic; Michihiro Abe, Ota Clinic; Noriaki Konishi, Konishi Gastrointestinal Medicine Clinic; Sakiko Arai, Arai Clinic; Masateru Goto, Goto Internal Medicine Clinic; Yasukazu Kimura, Kimura Internal Medicine Clinic and Yoshiyuki Osawa, Osawa Gastrointestinal Medicine Clinic; Akira Takahashi, Takahashi Internal Medicine Clinic; Takao Kumagai, Kumagai Clinic and Syu Hashimoto, Hashimoto Internal Medicine Clinic. The authors thank the collaborating medical institutions with cardiovascular specialists including Omagari Kousei Medical Center, Ikeda clinic, Yokote Municipal Hospital, Hiraga General Hospital, and Watanabe Intestinal-Cardiovascular Hospital. The authors thank the Japan Stroke Association and the Take Action for StroKe prevention in AF steering committee for their support and help throughout this study [35]. The authors would like to thank Donald Morisky, ScD, ScM, MSPH, Professor of Community Health Sciences, UCLA Fielding School of Public Health, for permission to use the MMAS-8. Use of the©MMAS is protected by US and International copyright laws. Permission for use is required. A license agreement is available from: Donald E. Morisky, MMAS Research (MORISKY) 16636 159th Place SE, Renton WA 98058, dmorisky@gmail.com. The authors would like to thank Dr. Ingrid de Ruiter, MBChB, PhD, of Edanz Medical Writing for providing initial medical writing support, which was funded by Bayer Yakuhin, Ltd. through EMC K.K. in accordance with Good Publication Practice (GPP3) guidelines. (http://www.ismpp.org/gpp3). The authors would also like to thank Forte Science Communications (Tokyo, Japan) for editorial assistance. The Akita study group representative, Akira Takahashi: chonsuke@kg8.so-net.ne.jp.
Funding Information:
A Suzuki has received a consultation fee from Bayer Yakuhin, Ltd. and an honorarium for a scientific meeting from Pfizer Japan Inc. Y Ikeda has received a consultation fee from Bayer Yakuhin, Ltd. and an honorarium for a scientific lecture from Daiichi Sankyo Co., Ltd. M Sasaki has received a consultation fee from Bayer Yakuhin, Ltd. H Matsuoka has received a consultation fee and a technical guidance fee from Bayer Yakuhin, Ltd., an honorarium for a scientific lecture from Bristol-Myers Squibb K.K., and an honorarium for a manuscript and a scientific lecture from Daiichi Sankyo Co., Ltd. A Takahashi has received a consultation fee and an honorarium for his participation as a general practitioner in this study from Bayer Yakuhin, Ltd. T Okamura has received a consultation fee and honoraria for scientific lectures from Bayer Yakuhin, Ltd., an honorarium for an annual scientific meeting from Daiichi Sankyo Co., Ltd., and a grant from the Japan Agency for Medical Research and Development. S Akiyama, F Ono and N Yoshihara are employees of Bayer Yakuhin, Ltd.
Funding Information:
This study followed the Ethical Guidelines for Human Clinical Research issued by the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare. Documented approval by the Institutional Ethics Committee/Institutional Review Board at the Research Institute for Brain and Blood Vessels-Akita on behalf of all participating clinics was received prior to the start of the study on October 5, 2015 (Approval number:15–10). This study was approved by the clinical research promotion network, Osaka Japan on August 27, 2015. Patients were required to provide written, informed consent to take part in the surveys if they chose to do so. In terms of data from medical chart review, they were secondary data collected in routine medical practice, and chart review was conducted anonymously; therefore, individual informed consent for data use was not required.
Publisher Copyright:
© 2019 The Author(s).
PY - 2019/10/24
Y1 - 2019/10/24
N2 - Background: Care coordination between general practitioners (GPs) and cardiovascular specialists is expected to play a key role in establishing appropriate oral anticoagulant (OAC) treatment in atrial fibrillation (AF) patients. The aim of this study was to assess the impact of care coordination on oral anticoagulant therapy in the management of AF in Japan. Methods: This study was a multi-center, single-arm, prospective cohort study with retrospective chart and claims data review for historical controls. The study included three study periods: a 12-month pre-campaign period; a 12-month campaign period for AF screening and care coordination; and a 3-month post-campaign period for follow-up of care coordination. During the campaign period, patients aged ≥65 years who attended participating GP clinics underwent opportunistic AF screening by GPs under the campaign. At the discretion of the GP, newly diagnosed AF patients after the screening were referred to a cardiovascular specialist for care coordination. To assess the impact of care coordination and evaluate the effects of the campaign, implementation of care coordination, antithrombotic therapies, and patient-reported outcomes were compared between patients with and without care coordination, and between patients during the pre-campaign and campaign periods. Results: There were 86 newly diagnosed AF patients during the pre-campaign period and 90 during the campaign period. The percentage of patients with care coordination increased from 3.5% (3/86) in the pre-campaign period to 14.4% (n = 13/90) during the campaign period. The percentage of patients who received OAC therapies, according to the definition from the Japanese AF medication guideline, increased from 55.8% (48/86) to 71.1% (64/90) during the campaign period regardless of care coordination. Younger patients were referred to cardiovascular specialists for care coordination. Implementation of OAC therapy did not differ between patients with and without care coordination. Adherence to OAC therapy was low regardless of care coordination. Conclusions: This GP-targeted campaign was effective at raising awareness regarding the implementation of care coordination and appropriate OAC therapy at local clinical practices in Japan. Improvement of adherence to OAC therapy in elderly patients is a critical issue, and measures such as education programs targeted to patients and healthcare professionals should be undertaken.
AB - Background: Care coordination between general practitioners (GPs) and cardiovascular specialists is expected to play a key role in establishing appropriate oral anticoagulant (OAC) treatment in atrial fibrillation (AF) patients. The aim of this study was to assess the impact of care coordination on oral anticoagulant therapy in the management of AF in Japan. Methods: This study was a multi-center, single-arm, prospective cohort study with retrospective chart and claims data review for historical controls. The study included three study periods: a 12-month pre-campaign period; a 12-month campaign period for AF screening and care coordination; and a 3-month post-campaign period for follow-up of care coordination. During the campaign period, patients aged ≥65 years who attended participating GP clinics underwent opportunistic AF screening by GPs under the campaign. At the discretion of the GP, newly diagnosed AF patients after the screening were referred to a cardiovascular specialist for care coordination. To assess the impact of care coordination and evaluate the effects of the campaign, implementation of care coordination, antithrombotic therapies, and patient-reported outcomes were compared between patients with and without care coordination, and between patients during the pre-campaign and campaign periods. Results: There were 86 newly diagnosed AF patients during the pre-campaign period and 90 during the campaign period. The percentage of patients with care coordination increased from 3.5% (3/86) in the pre-campaign period to 14.4% (n = 13/90) during the campaign period. The percentage of patients who received OAC therapies, according to the definition from the Japanese AF medication guideline, increased from 55.8% (48/86) to 71.1% (64/90) during the campaign period regardless of care coordination. Younger patients were referred to cardiovascular specialists for care coordination. Implementation of OAC therapy did not differ between patients with and without care coordination. Adherence to OAC therapy was low regardless of care coordination. Conclusions: This GP-targeted campaign was effective at raising awareness regarding the implementation of care coordination and appropriate OAC therapy at local clinical practices in Japan. Improvement of adherence to OAC therapy in elderly patients is a critical issue, and measures such as education programs targeted to patients and healthcare professionals should be undertaken.
KW - Aging society
KW - Anticoagulants
KW - Atrial fibrillation
KW - Care coordination
KW - Opportunistic screening in primary care
KW - Regional medical care
UR - http://www.scopus.com/inward/record.url?scp=85074070684&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074070684&partnerID=8YFLogxK
U2 - 10.1186/s12872-019-1216-y
DO - 10.1186/s12872-019-1216-y
M3 - Article
C2 - 31651245
AN - SCOPUS:85074070684
SN - 1471-2261
VL - 19
JO - BMC Cardiovascular Disorders
JF - BMC Cardiovascular Disorders
IS - 1
M1 - 235
ER -